Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …

Plasma biomarkers for neurodegenerative disorders: ready for... : Current Opinion in
Psychiatry Plasma biomarkers for neurodegenerative disorders: ready for prime time …